CORD-19:775b90287b44353bee979abb0970a4666022f86d / 300852-301129 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"T17033","span":{"begin":0,"end":277},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The primary outcome was the risk of lapse in asthma control during follow-up, reported as episodes per 100 patientyears (PY), measured as any asthma-related hospitalization or emergency room visit, ≥2 oral corticosteroid (OCS) or ≥6 short-acting beta-agonists filled in 1 year."}

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T249","span":{"begin":0,"end":277},"obj":"Sentence"}],"text":"The primary outcome was the risk of lapse in asthma control during follow-up, reported as episodes per 100 patientyears (PY), measured as any asthma-related hospitalization or emergency room visit, ≥2 oral corticosteroid (OCS) or ≥6 short-acting beta-agonists filled in 1 year."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T1957","span":{"begin":45,"end":51},"obj":"Disease"},{"id":"T1958","span":{"begin":142,"end":148},"obj":"Disease"},{"id":"T54516","span":{"begin":45,"end":51},"obj":"Disease"},{"id":"T68034","span":{"begin":142,"end":148},"obj":"Disease"}],"attributes":[{"id":"A1957","pred":"mondo_id","subj":"T1957","obj":"http://purl.obolibrary.org/obo/MONDO_0004979"},{"id":"A1958","pred":"mondo_id","subj":"T1958","obj":"http://purl.obolibrary.org/obo/MONDO_0004979"},{"id":"A59106","pred":"mondo_id","subj":"T54516","obj":"http://purl.obolibrary.org/obo/MONDO_0004979"},{"id":"A87988","pred":"mondo_id","subj":"T68034","obj":"http://purl.obolibrary.org/obo/MONDO_0004979"}],"text":"The primary outcome was the risk of lapse in asthma control during follow-up, reported as episodes per 100 patientyears (PY), measured as any asthma-related hospitalization or emergency room visit, ≥2 oral corticosteroid (OCS) or ≥6 short-acting beta-agonists filled in 1 year."}

{"project":"CORD-19-PD-HP","denotations":[{"id":"T1369","span":{"begin":45,"end":51},"obj":"Phenotype"},{"id":"T1370","span":{"begin":142,"end":148},"obj":"Phenotype"}],"attributes":[{"id":"A1369","pred":"hp_id","subj":"T1369","obj":"http://purl.obolibrary.org/obo/HP_0002099"},{"id":"A1370","pred":"hp_id","subj":"T1370","obj":"http://purl.obolibrary.org/obo/HP_0002099"}],"text":"The primary outcome was the risk of lapse in asthma control during follow-up, reported as episodes per 100 patientyears (PY), measured as any asthma-related hospitalization or emergency room visit, ≥2 oral corticosteroid (OCS) or ≥6 short-acting beta-agonists filled in 1 year."}